Haemonetics underwent a major debt restructuring with total debt surging 295% to $1.2B while simultaneously improving profitability and operational efficiency.
The massive debt increase combined with strong operational performance suggests this was likely a strategic refinancing or acquisition financing rather than financial distress. The company appears to be positioning for growth investments while maintaining operational discipline, though the debt burden creates new financial risk that investors must monitor closely.
Haemonetics experienced a dramatic financial transformation with total debt exploding from $316M to $1.2B (+295%) while current liabilities nearly doubled, yet the company simultaneously delivered strong operational results with net income rising 43% to $168M and operating income up 35% to $222M. Interest expense paradoxically dropped 99% despite the debt increase, suggesting favorable refinancing terms, while the company reduced capital expenditures 41% and built cash reserves up 72% to $307M. This combination of massive debt restructuring alongside improved profitability and cash generation indicates strategic financial repositioning rather than operational distress, though the new debt level introduces significant leverage risk.
Debt increased 294.6% — substantial leverage increase; assess whether deployed for growth or covering losses.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Current liabilities surged 92.5% — significant near-term obligations; verify ability to meet short-term debt.
Cash position surged 71.6% — strong cash generation or capital raise providing significant financial cushion.
Net income grew 42.6% — bottom-line growth signals improving overall business health.
Capex reduced 40.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Current assets grew 21.6% — improving short-term liquidity or inventory/receivables build.
R&D investment increased 15.2% — signals commitment to future product development, though near-term margin impact.
Inventory built 15.1% — monitor whether demand supports this build or if write-downs may follow.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →